<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02278874</url>
  </required_header>
  <id_info>
    <org_study_id>13-016B-NPT</org_study_id>
    <nct_id>NCT02278874</nct_id>
  </id_info>
  <brief_title>High Risk Multiple Gestation Study</brief_title>
  <official_title>Development of Non-invasive Prenatal Diagnostic Test for Multiple Gestation Pregnancies Based on Fetal DNA Isolated From Maternal Blood</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Natera, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mount Sinai Hospital, New York</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Montefiore Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Long Island Jewish Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tufts Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Natera, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of the clinical study are to demonstrate the accuracy of our proprietary
      algorithm method to determine the genetic health of the developing fetuses in a multiple
      gestation pregnancy from a maternal blood sample. The long term goal of this study will be
      the development of a method of minimally invasive prenatal diagnosis that has a higher
      sensitivity and lower false positive rate in the intended population (e.g. multiple gestation
      pregnancies) than other currently available screening tests.

      This will result in fewer unnecessary amniocenteses and CVS procedures, which are associated
      with a risk of miscarriage.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2014</start_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Screening capability of NATUS algorithm in the form of a risk results classified as positive result for aneuploidy, negative result for aneuploidy or 'no call.'</measure>
    <time_frame>2 years</time_frame>
    <description>The primary outcome will be to confirm the diagnostic capability of NATUS risk results (a risk score eg 1:100) classified as positive result for aneuploidy, negative result for aneuploidy or 'no call.' The outcome will be determined as a risk score given for samples collected. This outcome will be compared to the diagnostic testing results of ploidy status.
The chromosomal status will be determined from the CVS or amniocentesis results, if available. A cheek swab or saliva sample will be collected from live-born children if there are no CVS or amniocentesis results. This will be used to determine the true ploidy status of the fetuses.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Trisomy 13</condition>
  <condition>Trisomy 18</condition>
  <condition>Trisomy 21</condition>
  <condition>Sex Chromosome Abnormalities</condition>
  <arm_group>
    <arm_group_label>Multiple gestation high risk pregnancies</arm_group_label>
    <description>women pregnant with twins or triplets at high risk for aneuploidy</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Maternal and Paternal blood samples

      CVS or Amniocentesis sample (optional)

      Child saliva sample (optional)

      *Biospecimen retention is optional portion of consent form
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Pregnant Women
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 or older at enrollment

          -  Clinically confirmed multiple gestation pregnancy

          -  Pregnancy at high risk for genetic aneuploidy as defined below:

               -  Confirmed positive aneuploidy by invasive testing

               -  Non invasive prenatal testing &quot;high risk&quot; result

               -  Serum screening risk of greater than 1:100

               -  Ultrasound abnormalities indicative of aneuploidy

                    -  Structural abnormality of the posterior fossa

                    -  Holoprosenencephaly

                    -  Structural cardiac anomaly

                    -  Omphalocele

                    -  Nuchal translucency greater than or equal to 3.5 mm or a nuchal fold greater
                       Hydrops of unknown etiology

               -  Age ≥ 38 years at delivery (if serum screening risk is not less than 1:100)

          -  Gestational age between ≥ 9 weeks, 0 days and ≤26 weeks 0 days by best obstetrical
             estimate

          -  Able to provide informed consent

        Exclusion Criteria:

          -  Women carrying singleton pregnancy

          -  Surrogate or egg donor used
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joanne Stone, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mt. Sinai Hospital, New York</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peer Dar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Montefiore Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rajeevi Madankumar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Long Island Jewish Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Errol Norwitz, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tufts Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Melissa Schirmer</last_name>
    <phone>650-249-9090</phone>
    <phone_ext>696</phone_ext>
    <email>research@natera.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vidya Iyer, MBBS</last_name>
      <phone>617-636-0186</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Hudson</last_name>
      <phone>718-405-8214</phone>
    </contact>
    <investigator>
      <last_name>Peer Dar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Long Island Jewish Medical Center</name>
      <address>
        <city>Glen Cove</city>
        <state>New York</state>
        <zip>11542</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernadette Smith</last_name>
      <phone>718-470-5563</phone>
    </contact>
    <investigator>
      <last_name>Rajeevi Madankumar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mt. Sinai Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meredith Miller</last_name>
      <phone>212-241-3888</phone>
    </contact>
    <investigator>
      <last_name>Joanne Stone, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.natera.com/clinical-trials</url>
  </link>
  <reference>
    <citation>Pergament E, Cuckle H, Zimmermann B, Banjevic M, Sigurjonsson S, Ryan A, Hall MP, Dodd M, Lacroute P, Stosic M, Chopra N, Hunkapiller N, Prosen DE, McAdoo S, Demko Z, Siddiqui A, Hill M, Rabinowitz M. Single-nucleotide polymorphism-based noninvasive prenatal screening in a high-risk and low-risk cohort. Obstet Gynecol. 2014 Aug;124(2 Pt 1):210-8. doi: 10.1097/AOG.0000000000000363.</citation>
    <PMID>25004354</PMID>
  </reference>
  <reference>
    <citation>Ehrich M, Deciu C, Zwiefelhofer T, Tynan JA, Cagasan L, Tim R, Lu V, McCullough R, McCarthy E, Nygren AO, Dean J, Tang L, Hutchison D, Lu T, Wang H, Angkachatchai V, Oeth P, Cantor CR, Bombard A, van den Boom D. Noninvasive detection of fetal trisomy 21 by sequencing of DNA in maternal blood: a study in a clinical setting. Am J Obstet Gynecol. 2011 Mar;204(3):205.e1-11. doi: 10.1016/j.ajog.2010.12.060. Epub 2011 Feb 18.</citation>
    <PMID>21310373</PMID>
  </reference>
  <reference>
    <citation>Palomaki GE, Kloza EM, Lambert-Messerlian GM, Haddow JE, Neveux LM, Ehrich M, van den Boom D, Bombard AT, Deciu C, Grody WW, Nelson SF, Canick JA. DNA sequencing of maternal plasma to detect Down syndrome: an international clinical validation study. Genet Med. 2011 Nov;13(11):913-20. doi: 10.1097/GIM.0b013e3182368a0e.</citation>
    <PMID>22005709</PMID>
  </reference>
  <reference>
    <citation>Sehnert AJ, Rhees B, Comstock D, de Feo E, Heilek G, Burke J, Rava RP. Optimal detection of fetal chromosomal abnormalities by massively parallel DNA sequencing of cell-free fetal DNA from maternal blood. Clin Chem. 2011 Jul;57(7):1042-9. doi: 10.1373/clinchem.2011.165910. Epub 2011 Apr 25.</citation>
    <PMID>21519036</PMID>
  </reference>
  <reference>
    <citation>Bianchi DW, Platt LD, Goldberg JD, Abuhamad AZ, Sehnert AJ, Rava RP; MatErnal BLood IS Source to Accurately diagnose fetal aneuploidy (MELISSA) Study Group. Genome-wide fetal aneuploidy detection by maternal plasma DNA sequencing. Obstet Gynecol. 2012 May;119(5):890-901. doi: 10.1097/AOG.0b013e31824fb482. Erratum in: Obstet Gynecol. 2012 Oct;120(4):957.</citation>
    <PMID>22362253</PMID>
  </reference>
  <reference>
    <citation>Palomaki GE, Deciu C, Kloza EM, Lambert-Messerlian GM, Haddow JE, Neveux LM, Ehrich M, van den Boom D, Bombard AT, Grody WW, Nelson SF, Canick JA. DNA sequencing of maternal plasma reliably identifies trisomy 18 and trisomy 13 as well as Down syndrome: an international collaborative study. Genet Med. 2012 Mar;14(3):296-305. doi: 10.1038/gim.2011.73. Epub 2012 Feb 2.</citation>
    <PMID>22281937</PMID>
  </reference>
  <reference>
    <citation>Norton ME, Brar H, Weiss J, Karimi A, Laurent LC, Caughey AB, Rodriguez MH, Williams J 3rd, Mitchell ME, Adair CD, Lee H, Jacobsson B, Tomlinson MW, Oepkes D, Hollemon D, Sparks AB, Oliphant A, Song K. Non-Invasive Chromosomal Evaluation (NICE) Study: results of a multicenter prospective cohort study for detection of fetal trisomy 21 and trisomy 18. Am J Obstet Gynecol. 2012 Aug;207(2):137.e1-8. doi: 10.1016/j.ajog.2012.05.021. Epub 2012 Jun 1.</citation>
    <PMID>22742782</PMID>
  </reference>
  <reference>
    <citation>Canick JA, Kloza EM, Lambert-Messerlian GM, Haddow JE, Ehrich M, van den Boom D, Bombard AT, Deciu C, Palomaki GE. DNA sequencing of maternal plasma to identify Down syndrome and other trisomies in multiple gestations. Prenat Diagn. 2012 Aug;32(8):730-4. doi: 10.1002/pd.3892. Epub 2012 May 14.</citation>
    <PMID>22585317</PMID>
  </reference>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 27, 2014</study_first_submitted>
  <study_first_submitted_qc>October 28, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 30, 2014</study_first_posted>
  <last_update_submitted>April 12, 2017</last_update_submitted>
  <last_update_submitted_qc>April 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Trisomy 13</keyword>
  <keyword>Trisomy 18</keyword>
  <keyword>Trisomy 21</keyword>
  <keyword>Sex Chromosome Abnormalities</keyword>
  <keyword>Monosomy X</keyword>
  <keyword>XXX</keyword>
  <keyword>XXY</keyword>
  <keyword>XYY</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Congenital Abnormalities</mesh_term>
    <mesh_term>Trisomy</mesh_term>
    <mesh_term>Down Syndrome</mesh_term>
    <mesh_term>Chromosome Aberrations</mesh_term>
    <mesh_term>Chromosome Disorders</mesh_term>
    <mesh_term>Sex Chromosome Aberrations</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

